← All whitepapers

AI that Earns its Place in Pharma Commercial

What to ask, where the value is and what to do before you pick your 2027 AI vendors. A field guide for pharma commercial leaders.

Almost every booth at this year’s pharma conferences led with the same word: agents. Almost every commercial leader asked the same question: which of these will actually show up in our numbers? In this field guide, Rahul Agarwal, SVP and GM of Healthcare and Life Sciences at Accellor, answers it with proof points from work in production. Use it to pressure-test your 2027 shortlist.

What's inside

  • The one question to ask any AI partner
    Ask what its AI has been trusted to do on its own, and what evidence earned that trust. Plus five levels of trust, four kinds of AI and three follow-up questions that separate real agents from relabeled software.
  • The 6% problem
    Why about 90% of organizations use AI but only about 6% see it in their numbers, why programs plateau between Stages 2 and 3, and why 70% of the value lies in how the work gets done.
  • Why content AI stalls at MLR review
    How a pre-review agent can speed medical, legal and regulatory review by sitting in front of the reviewer, not in place of one.
  • What it takes for 300 scientists to trust an agent
    The evidence that let a governed knowledge agent at a global pharma leader answer R&D questions with no reviewer in the loop.
  • Five moves before you pick your 2027 vendors
    Inventory, classify, place each function on the curve, pick one workflow and fund the evidence.

Get your free copy

Fill in your details and the download will be ready right away.

Thank you! Your copy is ready.
Download the PDF
Oops! Something went wrong. Please check your details and try again.